Adverum Biotechnologies (ADVM) announced the appointment of Jason Mitchell as chief commercial officer. In his new role, Mr. Mitchell will be responsible for setting the launch strategy and building the commercial infrastructure for ixoberogene soroparvovec, Adverum’s potential one-time intravitreal injection for the treatment of neovascular or wet age-related macular degeneration. Ixo-vec is currently being evaluated in the Phase 2 LUNA clinical trial. The company plans to announce LUNA 52-week data and pivotal program details in the 4th quarter of 2024. In addition, the company is on track to initiate the Ixo-vec pivotal program in the 1st half of 2025. Most recently, Mr. Mitchell was the head of sales & training for Apellis Pharmaceuticals (APLS).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADVM:
Questions or Comments about the article? Write to editor@tipranks.com